MX2017007595A - Inmunoterapia para enfermedad angiogenica. - Google Patents
Inmunoterapia para enfermedad angiogenica.Info
- Publication number
- MX2017007595A MX2017007595A MX2017007595A MX2017007595A MX2017007595A MX 2017007595 A MX2017007595 A MX 2017007595A MX 2017007595 A MX2017007595 A MX 2017007595A MX 2017007595 A MX2017007595 A MX 2017007595A MX 2017007595 A MX2017007595 A MX 2017007595A
- Authority
- MX
- Mexico
- Prior art keywords
- immunotherapy
- angiogenic disease
- medicinal composition
- angiogenic
- disease
- Prior art date
Links
- 230000002491 angiogenic effect Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 238000009169 immunotherapy Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464452—Transcription factors, e.g. SOX or c-MYC
- A61K39/464453—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención proporciona una composición farmacéutica que contiene un péptido de antígeno de cáncer para el tratamiento y la prevención de enfermedades angiogénicas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014251208 | 2014-12-11 | ||
PCT/JP2015/084709 WO2016093326A1 (ja) | 2014-12-11 | 2015-12-10 | 血管新生病の免疫療法 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017007595A true MX2017007595A (es) | 2018-03-01 |
Family
ID=56107503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017007595A MX2017007595A (es) | 2014-12-11 | 2015-12-10 | Inmunoterapia para enfermedad angiogenica. |
Country Status (12)
Country | Link |
---|---|
US (4) | US10525096B2 (es) |
EP (1) | EP3231438B1 (es) |
JP (1) | JP6266811B2 (es) |
KR (2) | KR20230141904A (es) |
CN (2) | CN108064163B (es) |
AU (1) | AU2015362379B2 (es) |
BR (1) | BR112017012381A2 (es) |
CA (1) | CA2970236A1 (es) |
ES (1) | ES2805094T3 (es) |
HK (1) | HK1251184A1 (es) |
MX (1) | MX2017007595A (es) |
WO (1) | WO2016093326A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2531142T3 (es) | 2005-10-17 | 2015-03-11 | Sloan Kettering Inst Cancer | Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden |
CA2645766A1 (en) | 2006-04-10 | 2007-10-25 | Sloan Kettering Institute For Cancer Research | Immunogenic wt-1 peptides and methods of use thereof |
AR076349A1 (es) | 2009-04-23 | 2011-06-01 | Int Inst Cancer Immunology Inc | Peptido auxiliar del antigeno del cancer |
EP2802347B1 (en) | 2012-01-13 | 2019-01-09 | Memorial Sloan Kettering Cancer Center | Immunogenic wt-1 peptides and methods of use thereof |
US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
US9919037B2 (en) | 2013-01-15 | 2018-03-20 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
WO2020071551A1 (ja) | 2018-10-05 | 2020-04-09 | 株式会社癌免疫研究所 | 良性腫瘍の予防または治療薬 |
JP2023525822A (ja) * | 2020-05-12 | 2023-06-19 | エルジー・ケム・リミテッド | 多量体t細胞調節性ポリペプチド及びその使用方法 |
CN112759634B (zh) * | 2021-01-21 | 2022-04-08 | 浙江辉肽生命健康科技有限公司 | 具有氨基酸结构feyieenky的生物活性肽及其制备方法和应用 |
EP4385519A1 (en) | 2021-08-12 | 2024-06-19 | International Institute of Cancer Immunology, Inc. | Pharmaceutical composition and method for treatment or prevention of cancer |
CN114652826B (zh) * | 2022-01-24 | 2022-10-14 | 景泽生物医药(合肥)有限公司 | 抗egfr抗体的用途 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2310052T3 (es) | 1998-09-30 | 2008-12-16 | Corixa Corporation | Composiciones y metodos para la inmunoterapia especifica de wt1. |
US7063854B1 (en) | 1998-09-30 | 2006-06-20 | Corixa Corporation | Composition and methods for WTI specific immunotherapy |
US7312243B1 (en) | 2003-08-29 | 2007-12-25 | Jay Pravda | Materials and methods for treatment of gastrointestinal disorders |
CN101580538B (zh) | 2003-11-05 | 2013-06-19 | 株式会社国际癌症免疫研究所 | Wt1衍生的hla-dr-结合抗原肽 |
DK1988163T3 (da) | 2006-02-22 | 2012-08-20 | Int Inst Cancer Immunology Inc | Hla-a*3303-begrænset wt1 peptid og farmaceutisk sammensætning omfattende det samme |
WO2008081701A1 (ja) | 2006-12-28 | 2008-07-10 | International Institute Of Cancer Immunology, Inc. | Hla-a*1101拘束性wt1ペプチド、およびそれを含む医薬組成物 |
EP3384926A1 (en) * | 2007-12-05 | 2018-10-10 | International Institute of Cancer Immunology, Inc. | Cancer vaccine composition |
AR076349A1 (es) * | 2009-04-23 | 2011-06-01 | Int Inst Cancer Immunology Inc | Peptido auxiliar del antigeno del cancer |
TWI646970B (zh) | 2012-12-17 | 2019-01-11 | 大塚製藥股份有限公司 | 活化輔助t細胞的方法 |
EP2762152A1 (en) * | 2013-02-05 | 2014-08-06 | Nitto Denko Corporation | WT1 peptide cancer vaccine composition for transdermal administration |
CA2840988A1 (en) * | 2013-02-05 | 2014-08-05 | Nitto Denko Corporation | Wt1 peptide cancer vaccine composition for mucosal administration |
-
2015
- 2015-12-10 CA CA2970236A patent/CA2970236A1/en active Pending
- 2015-12-10 ES ES15867628T patent/ES2805094T3/es active Active
- 2015-12-10 WO PCT/JP2015/084709 patent/WO2016093326A1/ja active Application Filing
- 2015-12-10 MX MX2017007595A patent/MX2017007595A/es unknown
- 2015-12-10 EP EP15867628.8A patent/EP3231438B1/en active Active
- 2015-12-10 AU AU2015362379A patent/AU2015362379B2/en active Active
- 2015-12-10 JP JP2016563738A patent/JP6266811B2/ja active Active
- 2015-12-10 KR KR1020237032204A patent/KR20230141904A/ko not_active Application Discontinuation
- 2015-12-10 BR BR112017012381-9A patent/BR112017012381A2/pt not_active Application Discontinuation
- 2015-12-10 CN CN201580075795.5A patent/CN108064163B/zh active Active
- 2015-12-10 US US15/534,895 patent/US10525096B2/en active Active
- 2015-12-10 KR KR1020177018573A patent/KR20170092660A/ko not_active IP Right Cessation
- 2015-12-10 CN CN202210394413.7A patent/CN114949171A/zh active Pending
-
2018
- 2018-08-22 HK HK18110775.0A patent/HK1251184A1/zh unknown
-
2019
- 2019-10-03 US US16/592,407 patent/US11369656B2/en active Active
- 2019-11-22 US US16/692,598 patent/US11413322B2/en active Active
-
2022
- 2022-06-17 US US17/843,165 patent/US20220313770A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2016093326A1 (ja) | 2016-06-16 |
EP3231438A1 (en) | 2017-10-18 |
US11413322B2 (en) | 2022-08-16 |
JP6266811B2 (ja) | 2018-01-24 |
US20200023029A1 (en) | 2020-01-23 |
KR20170092660A (ko) | 2017-08-11 |
KR20230141904A (ko) | 2023-10-10 |
BR112017012381A2 (pt) | 2018-06-19 |
CN114949171A (zh) | 2022-08-30 |
AU2015362379A1 (en) | 2017-07-13 |
CN108064163B (zh) | 2022-06-10 |
AU2015362379B2 (en) | 2020-05-14 |
CN108064163A (zh) | 2018-05-22 |
ES2805094T3 (es) | 2021-02-10 |
JPWO2016093326A1 (ja) | 2017-09-14 |
EP3231438A4 (en) | 2018-06-20 |
US20200078436A1 (en) | 2020-03-12 |
US20220313770A1 (en) | 2022-10-06 |
EP3231438B1 (en) | 2020-06-17 |
US20170368131A1 (en) | 2017-12-28 |
US10525096B2 (en) | 2020-01-07 |
HK1251184A1 (zh) | 2019-01-25 |
US11369656B2 (en) | 2022-06-28 |
CA2970236A1 (en) | 2016-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017007595A (es) | Inmunoterapia para enfermedad angiogenica. | |
CL2018001000A1 (es) | Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr. | |
PH12018500380A1 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
MX2018005720A (es) | Anticuerpos pd-l1, fragmento de union al antigeno del mismo, y aplicacion medica de ello. | |
PH12017500002A1 (en) | Anti-cdh6 antibody drug conjugates | |
PH12016501618A1 (en) | Anti-dll3 antibodies and drug conjugates for use in melanoma | |
MX2017005152A (es) | Dosificacion y administracion de anticuerpos anti-cd40 no fucosilados. | |
NZ731467A (en) | Anti-tim3 antibodies and methods of use | |
MD20170032A2 (ro) | Anticorpi anti-TIGIT | |
MX2016013999A (es) | Conjugado farmaco-anticuerpo y su uso para el tratamiento contra el cancer. | |
MA40049A (fr) | Anticorps monoclonaux dirigés contre l'épitope her2 et procédés d'utilisation de ceux-ci | |
PH12018501043A1 (en) | Site specific her2 antibody drug conjugates | |
PH12016502061A1 (en) | Novel antii-rnf43 antibodies and methods of use | |
MX2016012124A (es) | Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos. | |
PH12017500406A1 (en) | Novel anti-mfi2 antibodies and methods of use | |
MX2018006249A (es) | Nuevos anticuerpos anti-emr2 y metodos de uso. | |
EP3199627A4 (en) | Tumor antigen peptides | |
IN2014MU00303A (es) | ||
PH12018500254A1 (en) | Combinations of an ox40 antibody and a tlr4 modulator and uses thereof | |
PH12016501841A1 (en) | Immunosuppressant formulation | |
PH12017500602A1 (en) | Methods for treating ocular conditions | |
NZ734750A (en) | Cancer therapy with a parvovirus combined with bevacizumab | |
EP3231867A4 (en) | Tumor antigen peptide | |
EP3223016A4 (en) | Peptides for targeting gastric cancer, and medical use thereof | |
IN2014CH00386A (es) |